Health Condition 1: C91- Lymphoid leukemia Health Condition 2: C92- Myeloid leukemia Health Condition 3: D701- Agranulocytosis secondary to cancer chemotherapy
Conditions
Interventions
Intervention1: Granulocyte Transfusion: Patients will receive antibiotics and other supportive care measures as per departmental policy with granulocytes.The granulocyte product will be infused throug
the prospective granulocyte donor will thus not be primed the previous evening. Overall recovery will be defined as the first of two consecutive days with an ANC 1000 cells/ ? L without granulocyte s
Sponsors
TATA MEMORIAL HOSPITAL
Eligibility
Inclusion criteria
Inclusion criteria: I. Children 1-18 years of age II. Subjects diagnosed and treated with hematolymphoid neoplasm. III. ANC 5 days IV. Carbepenem resistant gram-negative sepsis
Exclusion criteria
Exclusion criteria: I. Any subject requiring more than fluid boluses (20ml/kg) to correct hypotension II. Any subject admitted in intensive care unit III. Any subject with ejection fraction IV. Any subject with necrotizing enterocolitis V. Any subject diagnosed with solid tumor VI. Subjects previously enrolled in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To estimate the effect of granulocyte transfusion on 30 day mortality 2. To estimate the effect of granulocyte transfusion on ICU transferTimepoint: Thirty days from the day of Granulocyte administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess the time to fever resolution in hours 2.To determine the time to negative blood culture in days 3.To evaluate the length of hospital stay in days 4.To assess adverse events due to granulocyte infusionTimepoint: From the day of enrolment in the study till discharge from hospitalization | — |
Countries
India
Contacts
Public ContactDr SHYAM SRINIVASAN
Tata Memorial Hospital, Mumbai
Outcome results
None listed